SCHEMBL29809802

SCHEMBL29809802

N[C@@H](Cc1cn(S(=O)(=O)O)c2ccccc12)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.62
ALDH1A1 P00352 1/20 0.62
RECQL P46063 1/20 0.62
HTR6 P50406 6/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
MPO P05164 1/20 0.47
TSHR P16473 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
HIF1A Q16665 1/20 0.47
SCN9A Q15858 1/20 0.46
IDE P14735 1/20 0.46
PTGS2 P35354 1/20 0.45
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indoximod SCHEMBL30024540 0.83 MAPT (0.64) MAPTALDH1A1RECQLKMT2AKDM4E
Indoximod SCHEMBL18396403 0.83 MAPT (0.64) MAPTALDH1A1RECQLKMT2AKDM4E
1-Methyltryptophan SCHEMBL22393196 0.83 MAPT (0.64) MAPTALDH1A1RECQLKMT2AKDM4E
SCHEMBL838015 0.82 HTR6 (0.64) MAPTALDH1A1RECQLHTR6KDM4E
SCHEMBL838017 0.82 HTR6 (0.64) MAPTALDH1A1RECQLHTR6KDM4E
Indoximod SCHEMBL18395635 0.82 MAPT (0.63) MAPTALDH1A1RECQLKMT2AKDM4E
1-Methyltryptophan SCHEMBL21747173 0.82 MAPT (0.63) MAPTALDH1A1RECQLKMT2AKDM4E
SCHEMBL1079740 0.80 MAPT (0.68) MAPTALDH1A1RECQLKMT2AKDM4E
SCHEMBL1079739 0.80 MAPT (0.68) MAPTALDH1A1RECQLKMT2AKDM4E
SCHEMBL16281039 0.80 MAPT (0.68) MAPTALDH1A1RECQLKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094701-A TLR3 binding bicyclic peptide ligands 2026-05-26 CN claimed
WO-2025099047-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) BICYCLETX LIMITED (GB) 2025-05-15 WO claimed
WO-2025046244-A1 TLR3 BINDING BICYCLIC PEPTIDE LIGANDS BICYCLETX LIMITED (GB) 2025-03-06 WO claimed
EP-4274838-B1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LTD (GB) 2024-09-25 EP claimed
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2024-04-04 US claimed
CN-117529489-A Bicyclic peptide ligands specific for NK cells 拜斯科技术开发有限公司 2024-02-06 CN claimed
EP-4274838-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BicycleTx Limited (GB) 2023-11-15 EP claimed
WO-2022148974-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2022-07-14 WO claimed
CN-122094701-A TLR3 binding bicyclic peptide ligands 2026-05-26 CN disclosed
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof RAYZEBIO, INC. (US) 2025-07-10 US disclosed
WO-2025099047-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1) BICYCLETX LIMITED (GB) 2025-05-15 WO disclosed
WO-2025046244-A1 TLR3 BINDING BICYCLIC PEPTIDE LIGANDS BICYCLETX LIMITED (GB) 2025-03-06 WO disclosed
EP-4274838-B1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LTD (GB) 2024-09-25 EP disclosed
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2024-04-04 US disclosed
CN-117529489-A Bicyclic peptide ligands specific for NK cells 拜斯科技术开发有限公司 2024-02-06 CN disclosed
EP-4274838-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BicycleTx Limited (GB) 2023-11-15 EP disclosed
WO-2022148974-A2 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS PBK, KLRK1, MICA MAPT 4099/4885ALDH1A1 4552/4885RECQL 3990/4885
US-20250222146-A1 Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof SSTR2, SSTR4, SSTR5 MAPT 3475/4885ALDH1A1 4432/4885RECQL 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.